UgandaTuberculosis profile
Population  2014 38 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 4.5 (3.2–6.1) 12 (8.4–16)
Mortality (HIV+TB only) 6.4 (5–8.1) 17 (13–21)
Prevalence  (includes HIV+TB) 60 (33–95) 159 (87–253)
Incidence  (includes HIV+TB) 61 (53–69) 161 (141–183)
Incidence (HIV+TB only) 28 (24–32) 73 (63–84)
         
Case detection, all forms (%) 72 (64–83)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.4 (0.6–2.2) 12 (6.8–19)
MDR-TB cases among notified pulmonary
TB cases
530 (230–830) 480 (270–770)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 26 079   1 499
Pulmonary, clinically diagnosed 11 854   468
Extrapulmonary 4 180   107
       
Total new and relapse 44 187    
Previously treated, excluding relapses 1 984    
Total cases notified 46 171    
Among 44 187 new and relapse cases:
3 316 (8%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 958 (8%) 737 (18%) 3 569
Laboratory-confirmed RR-/MDR-TB cases     255
Patients started on MDR-TB treatment ***     213
TB/HIV 2014 Number (%)
TB patients with known HIV status 43 883 (95)
HIV-positive TB patients 19 612 (45)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 19 211 (98)
HIV-positive TB patients on antiretroviral therapy (ART) 15 877 (81)
HIV-positive people screened for TB 729 268  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (75) 44 605
Previously treated cases, excluding relapse, registered in 2013 (67) 2 572
HIV-positive TB cases, all types, registered in 2013 (73) 16 762
RR-/MDR-TB cases started on second-line treatment in 2012 (80) 41
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 3.6
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.7
Sites performing Xpert MTB/RIF 74
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 24
% Funded domestically 10%
% Funded internationally 69%
% Unfunded 21%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-24 Data: www.who.int/tb/data